Q2 2026 Earnings Beats at SKWD, BIO, KTOS, and WEYS Signal Broad US Sector Resilience

The Quick Take

• SKWD beat Q2 EPS by 23%: $1.30 actual vs $1.06 estimate, with a GF Score of 84/100 reflecting strong quality metrics
• Bio-Rad (BIO) posted $13.85 EPS vs $3.07 estimate — a 351% beat likely driven by non-recurring valuation or investment gains
• Kratos Defense (KTOS) delivered $0.21 EPS on $458.8M revenue, reflecting sustained defense procurement tailwinds
• Weyco Group (WEYS) reported $1.39 EPS and $62M revenue, a stable mid-cap footwear result with limited institutional momentum

The Q2 2026 reporting season delivered earnings beats across four distinct US sectors — specialty insurance, life sciences instrumentation, defense electronics, and footwear — with GuruFocus raising valuation questions for each post-beat. Skyward Specialty Insurance logged a 23% EPS beat at $1.30 vs $1.06 estimate and achieved a GF Score of 84/100, while Kratos Defense posted $458.8M in revenue and $0.21 EPS reflecting sustained DoD procurement. Bio-Rad's massive $13.85 EPS beat against a $3.07 estimate signals one-time valuation items rather than operational step-change. The breadth of results reinforces a pattern of US earnings improvement beyond large-cap technology names into defensive and cyclical sectors.

SKWD's result stands out because specialty insurance has faced rising catastrophe losses and geopolitical risk premiums in 2026; a 23% EPS beat implies disciplined underwriting that outpaced the headwinds. Peers such as Kinsale Capital and RLI Corp may see sympathy moves if the beat confirms sector-wide margin improvement. KTOS's $458.8M revenue positions it alongside peers HEICO and Parsons Corp as beneficiaries of elevated DoD defense electronics spending. BIO's extreme EPS gap is an outlier that warrants close reading of one-time items before projecting forward earnings. Weyco's steady $62M revenue in footwear confirms the brand's niche durability but limits its appeal for institutional rotation.

Watch Q3 guidance from each name: SKWD's renewal pricing commentary will confirm or refute margin durability through hurricane season; KTOS DoD contract announcements in drone and directed-energy systems determine backlog trajectory; and BIO's Q3 guidance reveals whether the $13.85 EPS normalizes. The macro variable governing all four names is the Federal Reserve's rate path — higher-for-longer rates benefit SKWD's investment income and compress biotech and defense capex financing simultaneously, creating divergent outcomes within the same earnings cohort.

Synthesized from 4 sources.